Panelists on PharmTech AI Pulse Check debate SURPASS, a new digital-twin trial program, regulatory acceptance, and the data-cleanup burden it will create.
Feature|Videos|May 28, 2024
A Different CDMO Experience: Q&A With Scorpius’ President & COO Joe Payne
Author(s)Scorpius BioManufacturing
Joe Payne, Scorpius BioManufacturing, comments on the unique needs of today's biopharmaceutical companies looking to develop and manufacture small-volume, early-stage large molecules.
Watch the video and learn more:
- Learn about Scorpius’ president and COO, Joe Payne, as a thought leader who is also approachable, energetic, and in-tune with client needs.
- Learn about Scorpius’ competitive advantages in biomanufacturing of small-volume, early-stage large molecules.
- Learn what it takes to produce an end product that can be shared with both prospective clients and prospective employees.
Related to this article
Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
Germany is home to several prominent pharma companies and more than 1000 innovative biotechs.
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
Trending on Pharmaceutical Technology
1
Germany’s Medical Biotechnology Sector is Flourishing
2
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
3
Formulation Strategies for Next-Generation Multiagonists
4
First-in-Human Trial Speed: Why FDA Trails China
5